Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niacin + endotoxin
- Development stage
- Unknown
- Lead developer
- University of Pennsylvania
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This entry refers to a specific experimental combination used by the University of Pennsylvania in the Genetics of Evoked Responses to Niacin and Endotoxemia (GENE) study. The protocol involves the administration of niacin (in both immediate-release and extended-release formulations) and a low-dose injection of endotoxin (lipopolysaccharide) to healthy volunteers. Niacin is a lipid-modifying agent that acts primarily through the G protein-coupled receptor HCAR2 (GPR109A) to inhibit lipolysis and induce skin flushing. Endotoxin is used as a standardized inflammatory stimulus that activates the Toll-like receptor 4 (TLR4) pathway. The study aims to identify genetic variants that influence individual variability in the physiological and inflammatory responses to these two distinct stimuli, which are relevant to cardiovascular disease and hypercholesterolemia.
- Brand names
- NiacorNiaspan
- Other names
- Vitamin B3Nicotinic acidLipopolysaccharideLPS
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on niacin + endotoxin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niacin + endotoxin.